Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)

Status Not yet recruiting

Clinical Trial Summary

The objective of this clinical trial is to evaluate the plasma pharmacokinetics of K9 in healthy subjects (Cohort 1) and the safety and treatment efficacy of K9 in patients with active Thyroid Eye Disease (Cohort 2). Participants will receive study medication one time or for up to 4 weeks. Participants will have blood drawn and/or complete eye exams and questionnaires. The planned duration of this study is 6 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06467435
Study type	Interventional
Source	University of Kentucky
Contact	Connie Dampier
Phone	859-562-0750
Email	dampier@email.uky.edu
Status	Not yet recruiting
Phase	Phase 1
Start date	July 2024
Completion date	May 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04583735` - A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease	Phase 4
Active, not recruiting	`NCT05002998` - TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study	Phase 4
Withdrawn	`NCT02422368` - The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease	Phase 2/Phase 3
Completed	`NCT03298867` - Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study	Phase 3
Recruiting	`NCT05987423` - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease	Phase 3
Recruiting	`NCT06112340` - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)	Phase 2/Phase 3
Recruiting	`NCT05517447` - Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease	Phase 3
Terminated	`NCT04737330` - A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)	Phase 3
Recruiting	`NCT05517421` - Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease	Phase 3
Recruiting	`NCT04311606` - Anti-VEGF Therapy for Acute Thyroid Eye Disease	Phase 2
Recruiting	`NCT06106828` - A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease (SatraGO-2)	Phase 3
Recruiting	`NCT06021054` - A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)	Phase 3
Not yet recruiting	`NCT06413043` - Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy	N/A
Not yet recruiting	`NCT06401044` - A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease	Phase 1
Recruiting	`NCT06384547` - A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)	Phase 3
Recruiting	`NCT06367517` - Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Recruiting	`NCT06275373` - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Enrolling by invitation	`NCT05241626` - AS-OCT of the Cornea in Thyroid Diseases
Active, not recruiting	`NCT05776121` - Study of ZB001 in Chinese Patients With Thyroid Eye Disease	Phase 1
Recruiting	`NCT04359979` - Tamsulosin for Thyroid Lid Retraction	N/A